ENABLING PRECISION DISCOVERY OF NEW TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES

IMIDomics’ Precision Discovery Platform integrates and analyzes clinical data, real world data, patient samples and biomolecular data

Inspired by Patients

Immune-Mediated Inflammatory Diseases (IMIDs) - including conditions like lupus, rheumatoid arthritis, Crohn’s disease and ulcerative colitis - afflict millions of people, creating health challenges that too often limit patients’ opportunities and significantly reduce their quality of life

Each year, billions of dollars are spent treating patients with these conditions, but current treatments are too often ineffective or come with challenging side effects. In fact, there are no curative medicines for these patients. The demand for new, effective therapies is therefore very significant – and these medicines can only come from a better understanding of these uniquely challenging diseases

Our story

IMIDomics’ work is powered by our Precision Discovery Platform. This advanced and highly-focused analytics solutions is built upon 15 years of innovation, forging connections with IMID patients and collecting a wealth of data and samples. This foundational work enables IMIDomics to lead in the discovery and development of IMID treatments

  • 2006

    IMID Clinical Consortium led by VHIR

    Cross-sectional IMID Grant Awarded

  • 2007

    Establishment of the IMID-Biobank

  • 2009

    ISO 9001 Certification

  • 2010

    First Cohort Collected

  • 2010

    HudsonAlpha Institute for Biotechnology Partnership

  • 2012

    Longitudinal IMID cohort grant awarded

  • 2012 - ongoing

    Continued Cohort Collection and Analysis

  • 2015

  • 2015

    IMIDOMICS FOUNDED

  • 2016

    Celgene Collaboration

  • 2018

    Becton, Dickinson and Company Collaboration

  • 2019

    H2020 EU Framework Grant

  • 2020

    Gossamer and BMS collaborations

Affiliations


...
...
...
...